CoChat

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 production. A lower activated and resting Treg subset was found in the Bev group compared with the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. Indeed, clinically responding patients in the Bev group showed a high percentage of non-suppressive Treg and a significant lower IL10 production compared with non-responding patients in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete population of effector T cell at T0 independent of the therapeutic regimen. This subset was maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining the circulation of the effector T cells. Results also provide a first rationale regarding the positive immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm8030380

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Evaluation of CD4 and CD8 T cell in the bevacizumab (Bev) group and the control (Ctrl) group by cytofluorimetry. (A) Analysis of the percentage of CD4 and CD8 T cells derived from patients belonging to the Bev group and the Ctrl group before (T0) and after III and VI cycles of therapies. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−. (B) Histograms represent the percentage of the different regulatory T cell subset (total, active, resting, and nonsuppressive) calculated on CD4+CD25+cells. Bev group and Ctrl group are represented with black and grey histograms, respectively.
Figure 1 Evaluation of CD4 and CD8 T cell in the bevacizumab (Bev) group and the control (Ctrl) group by cytofluorimetry. (A) Analysis of the percentage of CD4 and CD8 T cells derived from patients belonging to the Bev group and the Ctrl group before (T0) and after III and VI cycles of therapies. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−. (B) Histograms represent the percentage of the different regulatory T cell subset (total, active, resting, and nonsuppressive) calculated on CD4+CD25+cells. Bev group and Ctrl group are represented with black and grey histograms, respectively.CC BY · PubMed Central
Figure 2 Evaluation of CD4 and CD8 T cells in responding (R) and nonresponding (N-R) patients of the bevacizumab-treated group and the control group by cytofluorimetry. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−.
Figure 2 Evaluation of CD4 and CD8 T cells in responding (R) and nonresponding (N-R) patients of the bevacizumab-treated group and the control group by cytofluorimetry. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−.CC BY · PubMed Central
Figure 3 Analysis of CD4 and CD8 T cell subsets were carried out using the anti-CD3, anti-CD8, anti-CCR7, and anti-CD45RA MoAbs. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−. Dot plots show the expression of CD45RA and CCR7 molecules that identify different T cell subsets (T effector: CD45RA+CCR7−; T central memory: CD45RA−CCR7+, T naive: CD45RA+CCR7+, and T effector memory: CD45RA−CCR7−) at T0 and after III and VI cycles of therapy. Histograms represent the median values of the percentage of effector T cells (CD45RA+CCR7−) of 10 patients (five patients of R and N-R of both Bev group and Ctrl group) ± standard deviation. Black and grey columns correspond to responding and nonresponding patients, respectively.
Figure 3 Analysis of CD4 and CD8 T cell subsets were carried out using the anti-CD3, anti-CD8, anti-CCR7, and anti-CD45RA MoAbs. CD8 T cells were identified by gating the CD3+CD8+ cells, while the CD4 T cells were identified as CD3+CD8−. Dot plots show the expression of CD45RA and CCR7 molecules that identify different T cell subsets (T effector: CD45RA+CCR7−; T central memory: CD45RA−CCR7+, T naive: CD45RA+CCR7+, and T effector memory: CD45RA−CCR7−) at T0 and after III and VI cycles of therapy. Histograms represent the median values of the percentage of effector T cells (CD45RA+CCR7−) of 10 patients (five patients of R and N-R of both Bev group and Ctrl group) ± standard deviation. Black and grey columns correspond to responding and nonresponding patients, respectively.CC BY · PubMed Central
Figure 4 Total and non-suppressive Treg (totTreg and nsTreg, respectively) evaluated as fold increase after III or VI cycles of therapy compared with T0 (%TregIII or %TregVI/%TregT0). Black and grey columns correspond to Bev group and Ctrl group, respectively.
Figure 4 Total and non-suppressive Treg (totTreg and nsTreg, respectively) evaluated as fold increase after III or VI cycles of therapy compared with T0 (%TregIII or %TregVI/%TregT0). Black and grey columns correspond to Bev group and Ctrl group, respectively.CC BY · PubMed Central
Figure 5 Evaluation of IL10+cells at T0 and after III and VI cycles of treatment in bevacizumab patients and fold increase of the percentage of IL10+cells after III and VI cycles of therapy compared with T0 (%IL10 III or %IL10 VI/%IL10 T0) in R and N-R patients belonging to the Bev group.
Figure 5 Evaluation of IL10+cells at T0 and after III and VI cycles of treatment in bevacizumab patients and fold increase of the percentage of IL10+cells after III and VI cycles of therapy compared with T0 (%IL10 III or %IL10 VI/%IL10 T0) in R and N-R patients belonging to the Bev group.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Napoletano, C., Ruscito, I., Bellati, F., Zizzari, I. G., Rahimi, H., Gasparri, M. L., Antonilli, M., Panici, P. B., Rughetti, A., & Nuti, M.
Affiliations
  • Sapienza University of Rome (IT)
  • Humboldt-Universität zu Berlin (DE)
  • Azienda Ospedaliera Sant'Andrea (IT)
  • Policlinico Umberto I (IT)
Corresponding author
Napoletano, Chiara
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2019-03-18
Volume
8
Issue
3
Pages
380
ISSN
2077-0383 (ISSN-L)
OpenAlex
W2921909640
Cited by
43
References
34
Citations by year
2026: 3 · 2025: 7 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 4 · 2019: 3
FWCI
5.50
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
Associazione Italiana per la Ricerca sul Cancro (17432)
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
bevacizumab, recurrent ovarian cancer, regulatory T cells, effector T cells, CD4+ T cells, CD8+ T cells, IL-10, tumor immune microenvironment, anti-angiogenic therapy, chemotherapy response, peripheral blood mononuclear cells, combination immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.